ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 37 of 120 for:    zolpidem AND Hypnotics

Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Tablets

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00658541
Recruitment Status : Completed
First Posted : April 15, 2008
Results First Posted : January 20, 2010
Last Update Posted : May 3, 2011
Sponsor:
Information provided by:
Mutual Pharmaceutical Company, Inc.

Brief Summary:
The purpose of this study is to compare the bioequivalence of a test formulation of zolpidem tartrate tablets to an equivalent oral dose of the commercially available Ambien® (zolpidem tartrate tablets)in adult subjects under fed conditions.

Condition or disease Intervention/treatment Phase
Healthy Therapeutic Equivalency Drug: Zolpidem Tartrate 10 mg tablet Drug: Zolpidem Tartrate 10 mg tablet (Ambien®) Phase 1

Detailed Description:

The purpose of this study is to compare the bioequivalence of a test formulation of zolpidem tartrate tablets to an equivalent oral dose of the commercially available Ambien® (zolpidem tartrate tablets)in adult subjects under fed conditions.

Thirty-eight healthy, non-smoking, non-obese male and female volunteers at least 18 years of age will be randomly assigned in a crossover fashion to receive each of two zolpidem tartrate dosing regimens in sequence with a 7 day washout period between dosing periods. On the morning of Day 1, following an overnight fast of at least 10 hours and a standardized, high fat breakfast, subjects will receive either a single oral dose of the test formulation, zolpidem tartrate (1 x 10 mg tablet) or a single oral dose of the reference formulation, Ambien® (1 x 10 mg tablet). After a 7 day washout period, on the morning of Day 8 following an overnight fast of at least 10 hours and a standardized, high fat breakfast, subjects will receive the alternate regimen. Blood samples will be drawn from all participants before dosing and for 12 hours post dose at times sufficient to adequately define the pharmacokinetics of zolpidem tartrate. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout the confinement portion of the study for adverse reactions to the study drugs and/or procedures. Blood pressure and pulse rate will be obtained prior to dosing and at 0.5, 1, 2, 4 and 12 hours post-dose. All adverse events whether elicited by query, spontaneously reported or observed by clinic staff will be evaluated by the investigator and reported in the subject's case report form.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Randomized, Two-way Crossover, Single-dose, Open-label Study to Evaluate the Relative Bioequivalence of a Test Tablet Formulation of Zolpidem Tartrate 10mg, Compared to an Equivalent Dose of Ambien® in Fed, Healthy, Adult Subjects
Study Start Date : May 2004
Actual Primary Completion Date : May 2004
Actual Study Completion Date : May 2004

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Zolpidem Tartrate 10 mg Tablets
A single dose of zolpidem tartrate 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
Drug: Zolpidem Tartrate 10 mg tablet
10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.

Active Comparator: Zolpidem Tartrate (Ambien®) 10 mg Tablets
A single dose of Ambien® 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
Drug: Zolpidem Tartrate 10 mg tablet (Ambien®)
10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
Other Name: Ambien®




Primary Outcome Measures :
  1. Maximum Plasma Concentration (Cmax) for Zolpidem Tartrate [ Time Frame: serial pharmacokinetic blood samples drawn prior to dosing (hour 0), and then at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 4, 5, 6, 8, 10, and 12 hours after dose administration ]
    The maximum or peak concentration that zolpidem tartrate reaches in the plasma.

  2. Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Zolpidem Tartrate [ Time Frame: serial pharmacokinetic blood samples drawn prior to dosing (hour 0), and then at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 4, 5, 6, 8, 10, and 12 hours after dose administration ]
    The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable zolpidem tartrate concentration (t), as calculated by the linear trapezoidal rule.

  3. Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]for Zolpidem Tartrate [ Time Frame: serial pharmacokinetic blood samples drawn prior to dosing (hour 0), then 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 4, 5, 6, 8, 10, and 12 hours after dose administration ]
    The area under the zolpidem tartrate plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Sex: Male or Female; similar proportions of each preferred
  • Age: At least 18 years
  • Weight: must be 15% of ideal weight for height and frame
  • Subjects must be in good health and physical condition as determined by medical history
  • Subjects must read and sign the Consent Form

Exclusion Criteria:

  • history of treatment for alcoholism, substance abuse, or drug abuse within past 24 months
  • history of malignancy, stroke, diabetes, cardiac, renal or liver disease
  • history of GERD, malabsorption syndrome, colon cancer, or chronic colitis, including Crohn's disease
  • history of treatment for asthma within the past five (5) years
  • history of mental depression, pulmonary disease, sleep apnea
  • females who are pregnant or lactating
  • history of hypersensitivity to zolpidem tartrate, or any hypnotic or sedative
  • conditions upon screening which might contraindicate or require that caution be used in the administration of zolpidem tartrate, including sitting systolic blood pressure below 90 mm Hg, or diastolic pressure below 50 mm Hg; heart rate less than 50 beats per minute after a 5-minute rest in a seated position
  • inability to read and/or sign the consent form
  • treatment with any other investigation drug during the four (4) weeks prior to the initial dosing for this study
  • subjects who have donated blood within four (4) weeks prior to the initial dosing for this study
  • subjects who smoke or use tobacco products or are currently using nicotine products (patches, gums, etc.) Three (3) months abstinence is required.

Additional Information:
Responsible Party: Kristin Arnold, Vice President R&D, Mutual Pharmaceutical
ClinicalTrials.gov Identifier: NCT00658541     History of Changes
Other Study ID Numbers: 04065
First Posted: April 15, 2008    Key Record Dates
Results First Posted: January 20, 2010
Last Update Posted: May 3, 2011
Last Verified: April 2011

Additional relevant MeSH terms:
Zolpidem
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action